Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Nephrology
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | Chronic Kidney Disease | Review

Strategies to prevent, diagnose and treat kidney disease related to systemic arterial hypertension: a narrative review from the Mexican Group of Experts on Arterial Hypertension

Authors: Silvia Palomo-Piñón, José Manuel Enciso-Muñoz, Eduardo Meaney, Ernesto Díaz-Domínguez, David Cardona-Muller, Fabiola Pazos Pérez, Emilia Cantoral-Farfán, Juan Carlos Anda-Garay, Janet Mijangos-Chavez, Neftali Eduardo Antonio-Villa, on behalf of the Mexican Group of Experts on Arterial Hypertension

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

This narrative review highlights strategies proposed by the Mexican Group of Experts on Arterial Hypertension endorsed to prevent, diagnose, and treat chronic kidney disease (CKD) related to systemic arterial hypertension (SAH). Given the growing prevalence of CKD in Mexico and Latin America caused by SAH, there is a need for context-specific approaches to address the effects of SAH, given the diverse population and unique challenges faced by the region. This narrative review provides clinical strategies for healthcare providers on preventing, diagnosing, and treating kidney disease related to SAH, focusing on primary prevention, early detection, evidence-based diagnostic approaches, and selecting pharmacological treatments. Key-strategies are focused on six fundamental areas: 1) Strategies to mitigate kidney disease in SAH, 2) early detection of CKD in SAH, 3) diagnosis and monitoring of SAH, 4) blood pressure targets in patients living with CKD, 5) hypertensive treatment in patients with CKD and 6) diuretics and Non-Steroidal Mineralocorticoid Receptor Inhibitors in Patients with CKD. This review aims to provide relevant strategies for the Mexican and Latin American clinical context, highlight the importance of a multidisciplinary approach to managing SAH, and the role of community-based programs in improving the quality of life for affected individuals. This position paper seeks to contribute to reducing the burden of SAH-related CKD and its complications in Mexico and Latin America.
Literature
1.
Wainstein M, Bello AK, Jha V, Harris DCH, Levin A, Gonzalez-Bedat MC, et al. International society of nephrology global kidney health atlas: structures, organization, and services for the management of kidney failure in Latin America. Kidney Int Suppl. 2021;11(2):e35-46.CrossRef
2.
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12(1):7–11.CrossRef
3.
Georgianos PI, Agarwal R. Hypertension in chronic Kidney Disease (CKD): diagnosis, classification, and therapeutic targets. Am J Hypertens. 2021;34(4):318–26.PubMedCrossRef
4.
Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, et al. Hypertens Nat Rev Dis Primer. 2018;4:18014.CrossRef
5.
Pecoits-Filho R, Sola L, Correa-Rotter R, Claure-Del Granado R, Douthat WG, Bellorin-Font E, et al. Kidney Disease in Latin America: current status, challenges, and the role of the ISN in the development of nephrology in the region. Kidney Int. 2018;94(6):1069–72.PubMedCrossRef
6.
Shang Z. Use of Delphi in health sciences research: a narrative review. Med (Baltim). 2023;102(7):e32829.CrossRef
7.
Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59(4):504–12.PubMedPubMedCentralCrossRef
8.
Kunes J, Zicha J. The interaction of genetic and environmental factors in the etiology of Hypertension. Physiol Res. 2009;58(Suppl 2):33–42.CrossRef
9.
Valenzuela PL, Carrera-Bastos P, Castillo-García A, Lieberman DE, Santos-Lozano A, Lucia A. Obesity and the risk of cardiometabolic Diseases. Nat Rev Cardiol. 2023;20(7):475–94.PubMedCrossRef
10.
He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: Cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346: f1325.PubMedCrossRef
11.
Filippou CD, Tsioufis CP, Thomopoulos CG, Mihas CC, Dimitriadis KS, Sotiropoulou LI, et al. Dietary approaches to stop Hypertension (DASH) Diet and blood pressure reduction in adults with and without Hypertension: a systematic review and Meta-analysis of Randomized controlled trials. Adv Nutr Bethesda Md. 2020;11(5):1150–60.CrossRef
12.
Hall ME, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, et al. Weight-loss strategies for Prevention and Treatment of Hypertension: A Scientific Statement from the American Heart Association. Hypertens Dallas Tex 1979. 2021;78(5):e38-50.
13.
14.
Inoue K, Streja E, Tsujimoto T, Kobayashi H. Urinary albumin-to-creatinine ratio within normal range and all-cause or cardiovascular mortality among U.S. adults enrolled in the NHANES during 1999–2015. Ann Epidemiol. 2021;55:15–23.PubMedCrossRef
15.
Mensah GA, Croft JB, Giles WH. The heart, kidney, and brain as target organs in Hypertension. Curr Probl Cardiol. 2003;28(2):156–93.PubMedCrossRef
16.
Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and cystatin C-Based equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737–49.PubMedPubMedCentralCrossRef
17.
Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive Drugs are the most nephroprotective and why? Expert Opin Pharmacother. 2010;11(16):2651–63.PubMedCrossRef
18.
Stevens PE, Levin A, Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic Kidney Disease: synopsis of the Kidney Disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825–30.PubMedCrossRef
19.
Agudelo-Botero M, Valdez-Ortiz R, Giraldo-Rodríguez L, González-Robledo MC, Mino-León D, Rosales-Herrera MF, et al. Overview of the burden of chronic Kidney Disease in Mexico: secondary data analysis based on the global burden of Disease Study 2017. BMJ Open. 2020;10(3): e035285.PubMedPubMedCentralCrossRef
20.
21.
Figueroa-Lara A, Gonzalez-Block MA, Alarcon-Irigoyen J. Medical expenditure for chronic Diseases in Mexico: the case of selected diagnoses treated by the Largest Care Providers. PLoS ONE. 2016;11(1): e0145177.PubMedPubMedCentralCrossRef
22.
Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and Heart Failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.PubMedCrossRef
23.
Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trøndelag Health Study (HUNT), Norway. Am J Kidney Dis off J Natl Kidney Found. 2003;42(3):466–73.CrossRef
24.
Kidney Disease. Improving global outcomes (KDIGO) blood pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic Kidney Disease. Kidney Int. 2021;99(3S):1–87.
25.
Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An Independent predictor of Ischemic Heart Disease. Arterioscler Thromb Vasc Biol. 1999;19(8):1992–7.PubMedCrossRef
26.
Zoppini G, Targher G, Chonchol M, Ortalda V, Negri C, Stoico V, et al. Predictors of estimated GFR decline in patients with type 2 Diabetes and preserved kidney function. Clin J Am Soc Nephrol CJASN. 2012;7(3):401–8.PubMedCrossRef
27.
Levey AS, Becker C, Inker LA. Glomerular filtration rate and Albuminuria for detection and staging of Acute and chronic Kidney Disease in adults: a systematic review. JAMA. 2015;313(8):837–46.PubMedPubMedCentralCrossRef
28.
Weir MR. Microalbuminuria and Cardiovascular Disease. Clin J Am Soc Nephrol CJASN. 2007;2(3):581–90.PubMedCrossRef
29.
Chen SC, Su HM, Tsai YC, Huang JC, Chang JM, Hwang SJ, et al. Framingham risk score with cardiovascular events in chronic Kidney Disease. PLoS ONE. 2013;8(3): e60008.PubMedPubMedCentralCrossRef
30.
Grams ME, Sang Y, Ballew SH, Carrero JJ, Djurdjev O, Heerspink HJL, et al. Predicting timing of clinical outcomes in patients with chronic Kidney Disease and severely decreased glomerular filtration rate. Kidney Int. 2018;93(6):1442–51.PubMedPubMedCentralCrossRef
31.
Xu R, Sun S, Huo Y, Yun L, Huang S, Li G, et al. Effects of ACEIs Versus ARBs on Proteinuria or Albuminuria in primary Hypertension. Med (Baltim). 2015;94(39):e1560.CrossRef
32.
Chu CD, Powe NR, McCulloch CE, Banerjee T, Crews DC, Saran R, et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with Albuminuria. Hypertens Dallas Tex 1979. 2021;77(1):94–102.
33.
Levey AS, Inker LA. Assessment of Glomerular Filtration Rate in Health and Disease: a state of the Art Review. Clin Pharmacol Ther. 2017;102(3):405–19.PubMedCrossRef
34.
Levey AS, Stevens LA, Schmid CH, Zhang Y (Lucy), Castro AF, Feldman HI. A New Equation to Estimate Glomerular Filtration Rate, et al. editors. Ann Intern Med. 2009;150(9):604–12.
35.
Beauvieux MC, Le Moigne F, Lasseur C, Raffaitin C, Perlemoine C, Barthe N, et al. New predictive equations improve monitoring of kidney function in patients with Diabetes. Diabetes Care. 2007;30(8):1988–94.PubMedCrossRef
36.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461–70.PubMedCrossRef
37.
Rule AD, Rodeheffer RJ, Larson TS, Burnett JC, Cosio FG, Turner ST, et al. Limitations of estimating glomerular filtration rate from serum creatinine in the general population. Mayo Clin Proc. 2006;81(11):1427–34.PubMedCrossRef
38.
Piéroni L, Bargnoux AS, Cristol JP, Cavalier E, Delanaye P. Did Creatinine Standardization give benefits to the evaluation of glomerular filtration rate? EJIFCC. 2017;28(4):251–7.PubMedPubMedCentral
39.
Alaini A, Malhotra D, Rondon-Berrios H, Argyropoulos CP, Khitan ZJ, Raj DSC, et al. Establishing the presence or absence of chronic Kidney Disease: uses and limitations of formulas estimating the glomerular filtration rate. World J Methodol. 2017;7(3):73–92.PubMedPubMedCentralCrossRef
40.
41.
Bello AK, Hemmelgarn B, Lloyd A, James MT, Manns BJ, Klarenbach S, et al. Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes. Clin J Am Soc Nephrol CJASN. 2011;6(6):1418–26.PubMedCrossRef
42.
Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, et al. Change in albuminuria and subsequent risk of end-stage Kidney Disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7(2):115–27.PubMedPubMedCentralCrossRef
43.
Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T, et al. Early change in proteinuria as a surrogate end point for Kidney Disease progression: an individual patient meta-analysis. Am J Kidney Dis off J Natl Kidney Found. 2014;64(1):74–85.CrossRef
44.
Association of estimated. Glomerular filtration rate and albuminuria with mortality and end-stage renal Disease: a collaborative meta-analysis of Kidney Disease cohorts. Kidney Int. 2011;79(12):1331–40.CrossRef
45.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic Nephropathy: lessons from RENAAL. Kidney Int. 2004;65(6):2309–20.PubMedCrossRef
46.
Cepeda M, Pham P, Shimbo D. Status of ambulatory blood pressure monitoring and home blood pressure monitoring for the diagnosis and management of Hypertension in the US: an up-to-date review. Hypertens Res. 2023;46(3):620–9.PubMedPubMedCentralCrossRef
47.
48.
Thakkar HV, Pope A, Anpalahan M. Masked Hypertension: a systematic review. Heart Lung Circ. 2020;29(1):102–11.PubMedCrossRef
49.
Cupisti A, Ghiadoni L, Zullo C, Marchini M, Varricchio E, Puntoni A, et al. Home blood pressure measurement as a systematic tool for clinical practice in CKD patients: a real-world picture. Panminerva Med. 2018;60(1):1–7.PubMedCrossRef
50.
Wang C, Zhang J, Liu X, Li C, Ye Z, Peng H, et al. Reversed dipper blood-pressure pattern is closely related to severe renal and cardiovascular damage in patients with chronic Kidney Disease. PLoS ONE. 2013;8(2): e55419.PubMedPubMedCentralCrossRef
51.
Verdecchia P, Angeli F. How can we use the results of ambulatory blood pressure monitoring in clinical practice? Hypertens Dallas Tex 1979. 2005;46(1):25–6.
52.
Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Pede S, Porcellati C. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in Hypertension. Hypertens Dallas Tex 1979. 1998;32(6):983–8.
53.
Wang C, Zhang J, Deng W, Gong W, Liu X, Ye Z, et al. Nighttime Systolic blood-pressure load is correlated with target-organ damage Independent of ambulatory blood-pressure level in patients with non-diabetic chronic Kidney Disease. PLoS ONE. 2015;10(7): e0131546.PubMedPubMedCentralCrossRef
54.
Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J, et al. Masked Hypertension and elevated Nighttime blood pressure in CKD: Prevalence and Association with Target Organ damage. Clin J Am Soc Nephrol CJASN. 2016;11(4):642–52.PubMedCrossRef
55.
Ye X, Shafi S, Negrete A, Davis WN, Sarac E, Negrete AM, et al. Home blood pressure monitor use in patients with chronic Kidney Disease. Blood Press. 2016;25(5):280–5.PubMedCrossRef
56.
Staplin N, de la Sierra A, Ruilope LM, Emberson JR, Vinyoles E, Gorostidi M, et al. Relationship between clinic and ambulatory blood pressure and mortality: an observational cohort study in 59 124 patients. Lancet Lond Engl. 2023;401(10393):2041–50.CrossRef
57.
Borrelli S, Garofalo C, Gabbai FB, Chiodini P, Signoriello S, Paoletti E, et al. Dipping Status, ambulatory blood pressure control, Cardiovascular Disease, and Kidney Disease progression: a Multicenter Cohort Study of CKD. Am J Kidney Dis off J Natl Kidney Found. 2023;81(1):15-24e1.CrossRef
58.
Mansoor GA, White WB. Ambulatory blood pressure monitoring is a useful clinical tool in nephrology. Am J Kidney Dis off J Natl Kidney Found. 1997;30(5):591–605.CrossRef
59.
Amar J, Vernier I, Rossignol E, Bongard V, Arnaud C, Conte JJ, et al. Nocturnal blood pressure and 24-hour pulse pressure are potent indicators of mortality in hemodialysis patients. Kidney Int. 2000;57(6):2485–91.PubMedCrossRef
60.
Tripepi G, Fagugli RM, Dattolo P, Parlongo G, Mallamaci F, Buoncristiani U, et al. Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney Int. 2005;68(3):1294–302.PubMedCrossRef
61.
Ekart R, Kanič V, Pečovnik Balon B, Bevc S, Hojs R. Prognostic value of 48-hour ambulatory blood pressure measurement and cardiovascular mortality in hemodialysis patients. Kidney Blood Press Res. 2012;35(5):326–31.PubMedCrossRef
62.
Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol CJASN. 2007;2(6):1228–34.PubMedCrossRef
63.
Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP Control in CKD. J Am Soc Nephrol JASN. 2017;28(9):2812–23.PubMedCrossRef
64.
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis off J Natl Kidney Found. 2019;74(1):120–31.CrossRef
65.
Ari E, Fici F, Robles NR. Hypertension in kidney transplant recipients: where are we today? Curr Hypertens Rep. 2021;23(4):21.PubMedCrossRef
66.
Glicklich D, Lamba R, Pawar R. Hypertension in the kidney transplant recipient: overview of Pathogenesis, Clinical Assessment, and treatment. Cardiol Rev. 2017;25(3):102–9.PubMedCrossRef
67.
ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 practice guidelines for the management of arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the management of arterial Hypertension. J Hypertens. 2013;31(10):1925–38.CrossRef
68.
Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH et al. /ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018;138(17):e426–83.
69.
70.
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. Executive summary of the KDIGO 2021 Clinical Practice Guideline for the management of blood pressure in chronic Kidney Disease. Kidney Int. 2021;99(3):559–69.PubMedCrossRef
71.
SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.CrossRef
72.
Guerrot D, Humalda JK. Blood pressure targets in chronic Kidney Disease: an update on the evidence. Curr Opin Nephrol Hypertens. 2020;29(3):327–32.PubMedCrossRef
73.
ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, et al. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007;99(12A):21i–33i.
74.
Tsai WC, Wu HY, Peng YS, Yang JY, Chen HY, Chiu YL, et al. Association of Intensive Blood Pressure Control and Kidney Disease progression in nondiabetic patients with chronic Kidney Disease: a systematic review and Meta-analysis. JAMA Intern Med. 2017;177(6):792–9.PubMedPubMedCentralCrossRef
75.
Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J, et al. Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic Kidney Disease stages 3 to 5: a systematic review and Meta-analysis. JAMA Intern Med. 2017;177(10):1498–505.PubMedPubMedCentralCrossRef
76.
Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal systolic blood pressure target after SPRINT: insights from a Network Meta-Analysis of Randomized trials. Am J Med. 2017;130(6):707-719e8.PubMedCrossRef
77.
Dasgupta I, Zoccali C. Is the KDIGO systolic blood pressure target < 120 mm hg for chronic Kidney Disease Appropriate in Routine Clinical Practice? Hypertens Dallas Tex 1979. 2022;79(1):4–11.
78.
Coca A, Aranda P, Bertomeu V, Bonet A, Esmatjes E, Guillén F, et al. [Strategies for effective control of arterial Hypertension in Spain. Consensus document]. Rev Clin Esp. 2006;206(10):510–4.PubMedCrossRef
79.
Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF, et al. Chronic Kidney Disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet Lond Engl. 2013;382(9889):339–52.CrossRef
80.
Li H, Xue J, Dai W, Chen Y, Zhou Q, Chen W. Visit-to-visit blood pressure variability and risk of chronic Kidney Disease: a systematic review and meta-analyses. PLoS ONE. 2020;15(5): e0233233.PubMedPubMedCentralCrossRef
81.
Blood Pressure Lowering Treatment Trialists’ Collaboration, Ninomiya T, Perkovic V, Turnbull F, Neal B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic Kidney Disease: meta-analysis of randomised controlled trials. BMJ. 2013;347: f5680.PubMedCentralCrossRef
82.
Sinha AD, Agarwal R. Clinical pharmacology of antihypertensive therapy for the treatment of Hypertension in CKD. Clin J Am Soc Nephrol CJASN. 2019;14(5):757–64.PubMedCrossRef
83.
Strippoli GFM, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic Kidney Disease. Cochrane Database Syst Rev. 2006;2006(4):CD006257.PubMedPubMedCentral
84.
Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with Hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet Lond Engl. 2010;375(9721):1173–81.CrossRef
85.
Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, et al. Comparative effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in individuals with Advanced CKD: a Nationwide Observational Cohort Study. Am J Kidney Dis off J Natl Kidney Found. 2021;77(5):719-729e1.CrossRef
86.
Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, Kang YN. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with Hypertension and chronic Kidney Disease stage 3 to 5 and dialysis: a systematic review and meta-analysis. PLoS ONE. 2017;12(12): e0188975.PubMedPubMedCentralCrossRef
87.
Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, et al. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic Kidney Disease: systematic review and meta-analysis. Ren Fail. 2016;38(6):849–56.PubMedCrossRef
88.
Ghamami N, Chiang SHY, Dormuth C, Wright JM. Time course for blood pressure lowering of dihydropyridine calcium channel blockers. Cochrane Database Syst Rev. 2014;(8):CD010052.
89.
Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, et al. Calcium channel blockers versus other classes of Drugs for Hypertension. Cochrane Database Syst Rev. 2021;2021(10):CD003654.PubMedCentral
90.
Heerspink HJL, Kröpelin TF, Hoekman J, de Zeeuw D. Reducing Albuminuria as Surrogate Endpoint (REASSURE) Consortium. Drug-Induced reduction in Albuminuria is Associated with subsequent renoprotection: a Meta-analysis. J Am Soc Nephrol JASN. 2015;26(8):2055–64.PubMedCrossRef
91.
Abraham G, Almeida A, Gaurav K, Khan MY, Patted UR, Kumaresan M. Reno protective role of amlodipine in patients with hypertensive chronic Kidney Disease. World J Nephrol. 2022;11(3):86–95.PubMedPubMedCentralCrossRef
92.
Tamargo J. [New calcium channel blockers for the treatment of Hypertension]. Hipertens Riesgo Vasc. 2017;34(Suppl 2):5–8.PubMedCrossRef
93.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 Diabetes. N Engl J Med. 2017;377(7):644–57.PubMedCrossRef
94.
Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 Diabetes. N Engl J Med. 2016;374(11):1094.PubMed
95.
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–306.PubMedCrossRef
96.
Li N, Zhou G, Zheng Y, Lv D, Zhu X, Wei P, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: a meta-analysis. PLoS ONE. 2022;17(1): e0261986.PubMedPubMedCentralCrossRef
97.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac outcomes Trial-Blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet Lond Engl. 2005;366(9489):895–906.CrossRef
98.
Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin-angiotensin system inhibition in Advanced chronic Kidney Disease. N Engl J Med. 2022;387(22):2021–32.PubMedCrossRef
99.
Yoshimura M, Kawai M. Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin-aldosterone system. J Renin-Angiotensin-Aldosterone Syst JRAAS. 2010;11(2):124–6.PubMedCrossRef
100.
National High Blood Pressure Education Program. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Bethesda (MD): National Heart, Lung, and Blood Institute (US); 2004 . Available from: http://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK9630/​. Cited 2023 Apr 16.
101.
Hung SC, Kuo KL, Peng CH, Wu CH, Lien YC, Wang YC, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic Kidney Disease. Kidney Int. 2014;85(3):703–9.PubMedCrossRef
102.
Ecder T, Edelstein CL, Fick-Brosnahan GM, Johnson AM, Chapman AB, Gabow PA, et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic Kidney Disease. Am J Nephrol. 2001;21(2):98–103.PubMedCrossRef
103.
Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152–61.PubMedCrossRef
104.
Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney Diseases. Drug Dev Res. 2021;82(3):341–63.PubMedCrossRef
105.
Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant Hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet Lond Engl. 2015;386(10008):2059–68.CrossRef
106.
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on chronic Kidney Disease outcomes in type 2 Diabetes. N Engl J Med. 2020;383(23):2219–29.PubMedCrossRef
107.
Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, et al. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64(1):69–78.PubMedCrossRef
108.
Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84(12):934–42.PubMedCrossRef
109.
Kovesdy CP. Management of hyperkalaemia in chronic Kidney Disease. Nat Rev Nephrol. 2014;10(11):653–62.PubMedCrossRef
110.
Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with Kidney Disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211–21.PubMedCrossRef
111.
Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, Vishneva E, Zvereva T, et al. Emergency potassium normalization treatment including Sodium Zirconium Cyclosilicate: a phase II, Randomized, Double-blind, placebo-controlled study (ENERGIZE). Acad Emerg Med off J Soc Acad Emerg Med. 2020;27(6):475–86.CrossRef
Metadata
Title
Strategies to prevent, diagnose and treat kidney disease related to systemic arterial hypertension: a narrative review from the Mexican Group of Experts on Arterial Hypertension
Authors
Silvia Palomo-Piñón
José Manuel Enciso-Muñoz
Eduardo Meaney
Ernesto Díaz-Domínguez
David Cardona-Muller
Fabiola Pazos Pérez
Emilia Cantoral-Farfán
Juan Carlos Anda-Garay
Janet Mijangos-Chavez
Neftali Eduardo Antonio-Villa
on behalf of the Mexican Group of Experts on Arterial Hypertension
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03450-5

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue

Research

Drug utilization in patients starting haemodialysis with a focus on cardiovascular and antidiabetic medications: an epidemiological study in the Lazio region (Italy), 2016–2020

Research

The association between C-reactive protein levels and the risk of kidney stones: a population-based study

Research

Risk factors for short-term all-cause mortality in patients with end stage renal disease: a scoping review

Research

Improvement effects of transplanting pancreatic islet that previously incubated with biomaterials on the diabetic nephropathy in STZ- diabetic rats

Case Report

Polycystic intrahepatic infection caused by Enterococcus casseliflavus: a case report and literature review

Research

The moderating role of social support in the relationship between death anxiety and resilience among dialysis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits